GlassScriptPhysician profile
Amit N Shah
NPI 1629172051
$9,973.91
in general payments reported to CMS, 2019-2025
36 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $2,204 · 2021: $2,183 · 2022: $974 · 2023: $1,366 · 2024: $977 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.30 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,991.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,567.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,475.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $592.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.47 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $436.66 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Abbvie INC. | $396.48 | 2019-2025 | Ubrelvy |
| Astellas Pharma US INC | $339.98 | 2019-2024 | Veozah |
| Lilly USA, LLC | $298.35 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $295.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $269.75 | 2019-2021 | |
| Pfizer INC. | $239.76 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $238.25 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $201.31 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $158.81 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $149.44 | 2019-2025 | Repatha, Otezla, Otezla |
| Alkermes, INC. | $79.53 | 2019-2022 | |
| Eisai INC. | $78.72 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $57.62 | 2020-2021 | |
| Lundbeck LLC | $56.13 | 2020-2021 | |
| Abbott Laboratories | $52.84 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $48.90 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $47.84 | 2019 | |
| Shield Therapeutics INC | $47.18 | 2023-2024 | Accrufer |
| Esperion Therapeutics, INC. | $45.95 | 2020 | |
| Topcon Healthcare Solutions, INC. | $38.73 | 2020 | |
| Scilex Pharmaceuticals INC. | $24.68 | 2022 | |
| Antares Pharma, INC. | $23.85 | 2024 | Xyosted |
| Acadia Pharmaceuticals INC | $19.77 | 2019 | |
| Almatica Pharma LLC | $19.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.96 | 2022 | |
| Medtronic, INC. | $17.17 | 2022 | |
| Genzyme Corporation | $16.56 | 2019 | |
| Tactile Systems Technology INC | $15.63 | 2022 | |
| Ethicon US, LLC | $13.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.